ALNY(Alnylam Pharmaceuticals, Inc.) · 财务报表

ALNY(Alnylam Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$844.29M$1.04B$1.83B$2.25B$3.71B
毛利润$729.28M$897.24M$1.56B$1.94B$3.04B
营业利润−$708.65M−$785.07M−$282.18M−$176.88M$501.58M
净利润−$852.82M−$1.13B−$440.24M−$278.16M$313.75M
经营现金流−$641.69M−$541.27M$104.16M−$8.31M$524.08M
自由现金流−$718.07M−$613.33M$41.95M−$42.59M$465.38M
摊薄每股收益$-7.20$-9.30$-3.52$-2.18$2.33

Alnylam Pharmaceuticals, Inc. ALNY